Company intelligence / Profile preview
Aerium Therapeutics
Boston, Massachusetts, United Statesaeriumtx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Aerium Therapeutics was developing monoclonal antibodies with broad and potent activity against predominant variants of SARS-CoV-2, including those containing the F456L mutation. The company ceased operations in 2024 due to the emergence of new variants.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodiesSmall molecule antivirals
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Lausanne University Hospital (CHUV)École Polytechnique Fédérale de Lausanne (EPFL)Rockefeller UniversityFred Hutchinson Cancer Center
Beyond the preview
Go deeper on Aerium Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aerium Therapeutics.